Literature DB >> 24061549

Frequent triple-hit expression of MYC, BCL2, and BCL6 in primary lymphoma of the central nervous system and absence of a favorable MYC(low)BCL2 (low) subgroup may underlie the inferior prognosis as compared to systemic diffuse large B cell lymphomas.

Anna Brunn1, Inga Nagel, Manuel Montesinos-Rongen, Wolfram Klapper, Inga Vater, Werner Paulus, Volkmar Hans, Ingmar Blümcke, Joachim Weis, Reiner Siebert, Martina Deckert.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24061549     DOI： 10.1007/s00401-013-1169-7

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN： 0001-6322            Impact factor:   17.088


× No keyword cloud information.
  22 in total

1.  BCL2 expression is associated with a poor prognosis independent of cellular origin in primary central nervous system diffuse large B-cell lymphoma.

Authors:  Keishi Makino; Hideo Nakamura; Naoki Shinojima; Jun-Ichiro Kuroda; Shigetoshi Yano; Yoshiki Mikami; Akitake Mukasa
Journal:  J Neurooncol       Date:  2018-07-02       Impact factor: 4.130

2.  The mutational pattern of primary lymphoma of the central nervous system determined by whole-exome sequencing.

Authors:  I Vater; M Montesinos-Rongen; M Schlesner; A Haake; F Purschke; R Sprute; N Mettenmeyer; I Nazzal; I Nagel; J Gutwein; J Richter; I Buchhalter; R B Russell; O D Wiestler; R Eils; M Deckert; R Siebert
Journal:  Leukemia       Date:  2014-09-05       Impact factor: 11.528

3.  Prognostic impact of MYC protein expression in central nervous system diffuse large B-cell lymphoma: comparison with MYC rearrangement and MYC mRNA expression.

Authors:  Seung-Myoung Son; Sang-Yun Ha; Hae-Yong Yoo; Dongryul Oh; Seok-Jin Kim; Won-Seog Kim; Young-Hyeh Ko
Journal:  Mod Pathol       Date:  2016-09-30       Impact factor: 7.842

4.  Molecular features of a large cohort of primary central nervous system lymphoma using tissue microarray.

Authors:  Diego Villa; King L Tan; Christian Steidl; Susana Ben-Neriah; Muntadhar Al Moosawi; Tamara N Shenkier; Joseph M Connors; Laurie H Sehn; Kerry J Savage; David W Scott; Randy D Gascoyne; Graham W Slack
Journal:  Blood Adv       Date:  2019-12-10

5.  The Diagnosis and Treatment of Primary CNS Lymphoma.

Authors:  Louisa von Baumgarten; Gerald Illerhaus; Agnieszka Korfel; Uwe Schlegel; Martina Deckert; Martin Dreyling
Journal:  Dtsch Arztebl Int       Date:  2018-06-22       Impact factor: 5.594

6.  MYC protein expression in primary diffuse large B-cell lymphoma of the central nervous system.

Authors:  Kamraan Z Gill; Fabio Iwamoto; Ashleigh Allen; Daniela Hoehn; Vundavalli V Murty; Bachir Alobeid; Govind Bhagat
Journal:  PLoS One       Date:  2014-12-05       Impact factor: 3.240

7.  JMJD3 promotes survival of diffuse large B-cell lymphoma subtypes via distinct mechanisms.

Authors:  Yan Zhang; Long Shen; Dwayne G Stupack; Nan Bai; Jing Xun; Guosheng Ren; Jihong Han; Luyuan Li; Yunping Luo; Rong Xiang; Xiaoyue Tan
Journal:  Oncotarget       Date:  2016-05-17

8.  Metachronous extranodal natural killer/T-cell lymphoma of nasal type and primary testicular lymphoma.

Authors:  Young-In Maeng; Sun-Jae Lee
Journal:  Yeungnam Univ J Med       Date:  2020-09-11

Review 9.  Primary CNS lymphoma.

Authors:  Elizabeth H Phillips; Christopher P Fox; Kate Cwynarski
Journal:  Curr Hematol Malig Rep       Date:  2014-09       Impact factor: 3.952

10.  MYC and BCL2 overexpression is associated with a higher class of Memorial Sloan-Kettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system.

Authors:  Sehui Kim; Soo Jeong Nam; Dohee Kwon; Hannah Kim; Eunyoung Lee; Tae Min Kim; Dae Seog Heo; Sung Hye Park; Chul Woo Kim; Yoon Kyung Jeon
Journal:  BMC Cancer       Date:  2016-06-10       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.